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Macrolides are a class of valuable antibiotics that
include a macrolactone ring, at least one appended
sugar unit, and, in most cases, additional hydroxyl
or epoxide groups installed by cytochrome P450
enzymes. These functional groups contribute to
structural diversification and serve to improve the
bioactivity profiles of natural products. Here, we
have characterized in vitro two P450 enzymes from
the mycinamicin biosynthetic pathway of Micromo-
nospora griseorubida. First, MycCI was character-
ized as the C21 methyl hydroxylase of mycinamicin
VIII, the earliest macrolide form in the postpolyketide
synthase tailoring pathway. Moreover, we estab-
lished that optimal activity of MycCI depends on the
native ferredoxin MycCII. Second, MycG P450 cata-
lyzes consecutive hydroxylation and epoxidation
reactions with mycinamicin IV as initial substrate.
These reactions require prior dimethylation of 6-de-
oxyallose to mycinose for effective conversion by
the dual function MycG enzyme.
INTRODUCTION
The cytochrome P450 enzymes (P450s) form a very large family
of oxidative hemeproteins that are responsible for diverse
oxidative transformations across most life forms (Coon, 2005;
Guengerich, 2001). These reactions typically involve modifica-
tion of physiologic and xenobiotic compounds and include the
biosynthesis of various bioactive compounds (e.g., steroids, an-
tibiotics, and signaling molecules). Recent bacterial genome se-
quencing efforts have uncovered an unexpected large number of
genes encoding P450 enzymes. For example, the model actino-
mycete Streptomyces coelicolor A3(2) that produces actinorho-
din and undecylprodigiosin revealed the presence of 18 different
P450 genes (Bentley et al., 2002), whereas Streptomyces aver-950 Chemistry & Biology 15, 950–959, September 22, 2008 ª2008mitilis MA-4680, an avermectin producer, contains 33 P450s
(Ikeda et al., 2003), and Saccharopolyspora erythraea NRRL
23338, the erythromycin-producing bacterium, encodes 36
P450s (Oliynyk et al., 2007). In secondary metabolic pathways,
it is typical that P450 genes are integrated within the biosynthetic
cluster, where their products catalyze regio- and stereospecific
oxidation of precursors leading to structural diversity as well as
improved bioactivities of these molecules (Lamb et al., 2003;
Rix et al., 2002). Thus, cytochrome P450 enzymes EryF (Ander-
sen and Hutchinson, 1992) and EryK (Stassi et al., 1993) that are
encoded within the erythromycin biosynthetic gene cluster are
involved in the biosynthesis of erythromycin A. Specifically,
EryF hydroxylates the macrolactone precursor 6-deoxyerthro-
nolide B, whereas EryK is a macrolide hydroxylase resulting in
formation of erythromycin D. As prototypic P450 hydroxylases
involved in secondary metabolism, EryF and EryK exhibit strict
substrate specificity. In contrast, PikC cytochrome P450 in-
volved in the methymycin/neomethymycin and pikromycin
biosynthetic pathway of Streptomyces venezuelae has broader
substrate tolerance (Xue et al., 1998). PikC catalyzes the final
hydroxylation step toward the 12-membered ring macrolide
YC-17 and the 14-membered ring macrolide narbomycin to
produce methymycin/neomethymycin and pikromycin as major
products.
Mycinamicins, a series of macrolide antibiotics produced by
the rare actinomycete Micromonospora griseorubida, have
shown impressive activities against a spectrum of Gram-positive
strains, especially some antibiotic-resistant human pathogens
(Kinoshita et al., 1988; Satoi et al., 1980; Suzuki et al., 1990).
Stucturally, the major mycinamicin products of wild-type strain
M. griseorubida A11725, including mycinamicin I (M-I), II (M-II),
IV (M-IV), and V (M-V) (Figure 1), consist of a 16-membered
ring polyketide macrolactone substituted with 6-deoxyhexose
sugars desosamine and mycinose. Partial characterization of
the biosynthetic pathway for mycinamicins has been obtained
through analysis of blocked mutants and corresponding biocon-
version studies (Kinoshita et al., 1991a; Suzuki et al., 1990). More
recently, the nucleotide sequence of the complete mycinamicin
biosynthetic gene cluster has been reported (Anzai et al., 2003),Elsevier Ltd All rights reserved
Figure 1. Mycinamicin Post-PKS Biosynthetic Pathway and Organization of the Mycinamicin Biosynthetic Gene Cluster
Methyl groups introduced by O-methyltransferases and oxidation steps catalyzed by cytochrome P450 enzymes are highlighted in green and red, respectively.
Bold arrows represent the main pathway, whereas thin arrows indicate a shunt pathway. The dashed arrow indicates low-level conversion, as reported elsewhere
(Inouye et al., 1994). Color codes in the myc gene cluster are as follows: red, cytochrome P450 genes; purple, ferredoxin gene; indigo blue, polyketide synthetase
genes; blue, glycosyltransferase genes; green, O-methyltransferase genes; orange, deoxysugar biosynthetic genes; and yellow, self-resistance gene (rRNA
methyltransferase gene).
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fied (Figure 1).
Analysis of the 50 region of themyc gene cluster upstream from
the PKS locus revealed thatmycCI is located adjacent tomycCII,
which encodes a putative ferredoxin (Anzai et al., 2003). Since
the deduced amino acid sequences of mycCI and mycCII
show high sequence similarities to TylHI and TylHII (Figure 2), re-
spectively, that are likely responsible for hydroxylation at the C23
methyl group of tylactone (Baltz and Seno, 1981), the function of
MycCI and MycCII was accordingly proposed to mediate hy-
droxylation at the analogous C21 methyl group of protomycino-
lide IV (PML-IV) (Anzai et al., 2003) (Figure 1). On the basis of ge-
netic complementation analysis of a targeted mutant strain of
M. griseorubida, mycGwas presumed to encode a P450 enzyme
that catalyzes both hydroxylation and epoxidation at C14 and
C12/13 on the macrolactone ring of mycinamicin (Inouye et al.,
1994; Suzuki et al., 1990). In the current study, mycCI and
mycG genes were overexpressed in Escherichia coli, and the
functions of purified MycCI and MycG proteins were determinedChemistry & Biology 15, 950–in vitro using natural substrates derived from semi-synthesis or
isolated from wild-type or engineered strains of M. griseorubida
that accumulate key mycinamycin intermediates. Moreover,
specific roles have been proposed for both the desosamine
and mycinose sugar residues in the oxidative cascade leading
to M-II, the final product in the pathway.
RESULTS
Protein Sequence Analysis of MycCI and MycG
Comparison of the deduced amino acid sequences of MycCI and
MycG showed relatively low sequence identity (33%). In the phy-
logenetic tree (Figure 2) of selected bacterial macrolide biosyn-
thetic P450 enzymes, they were clustered in distinct branches,
suggesting these two unrelated P450 genes may have been inte-
grated into the mycinamicin biosynthetic gene cluster sequen-
tially from different ancestors, as opposed to being derived from
divergent evolution following duplication of a parental gene.
Specifically, MycG, as the first biosynthetic monooxygenase959, September 22, 2008 ª2008 Elsevier Ltd All rights reserved 951
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Biosynthetic P450 Mono-Oxygenases
The selected cytochrome P450s include OleP
(accession number AAA92553) [oleandomycin
pathway], ChmHI and ChmPI (accession numbers
AAS79447 and AAS79453) [chalcomycin path-
way], MycCI and MycG [mycinamicin pathway]
(accession numbers BAC57023 and BAA03672),
AmphL and AmphN (accession numbers
AAK73504 and AAK73509) [amphotericin path-
way], NysL and NysN (accession numbers
AAF71769 and AAF71771) [nystatin pathway],
PimD and PimG (accession numbers CAC20932
and CAC20928) [pimaricin pathway], TylHI and
TylI (accession numbers AAD41818 and
AAA21341) [tylosin pathway], EryF and EryK (ac-
cession numbers AAA26496 and YP-001102980)
[erythromycin pathway], and PikC (accession
numbers AAC68886) [pikromycin pathway]. The
numbers in parentheses indicate the macrolac-
tone ring size of the corresponding P450
substrate. Unless otherwise specified, all selected P450 enzymes are hydroxylases. The epoxidases are noted in italics. The enzymes marked with an asterisk
are presumed to mediate carboxylic acid formation. MycCI and MycG are highlighted in bold.characterized with an ability to catalyze both hydroxylation and
epoxidation steps, is clustered with two other epoxidases—
OleP (Rodriguez et al., 1995) and ChmPI (Ward et al., 2004) —
whereas MycCI is closely related to ChmHI (Ward et al., 2004)
and TylHI (Baltz and Seno, 1981), both of which are responsible
for methyl group hydroxylations of 16-membered ringmacrolides.
Interestingly, we revealed that the clustering of macrolide biosyn-
thetic P450s correlated with not only the functionalities (i.e., hy-
droxylases, epoxidases, or ones responsible for carboxylic acid
formation) but also the substrate macrolactone ring size, suggest-
ing that selection based on product structure derived from the up-
stream PKS biosynthetic system might be among the significant
factors directing evolution of secondary metabolic P450s.
Heterologous Expression of MycCI, MycCII, and MycG
The mycCI, mycCII, and mycG genes were overexpressed in
E. coli BL21(DE3), and the resulting proteins were purified (see
Supplemental Data available online). MycCI was overexpressed
as either a C- or N-terminal 63His tagged protein. After purifica-
tion using Ni-NTA agarose chromatography, the individual poly-
peptides showed molecular weights of approximately 44 and
45 kDa, corresponding to the estimated masses of C- and N-ter-
minal 63 His tagged MycCI. The wild-type MycCII (MycCII-wt,
m.w. 8 kDa) and N-terminal 63 His-tagged ferredoxin MycCII
(MycCII-NH, m.w. 10 kDa) were purified to homogeneity (see
Experimental Procedures). MycG expression was placed under
the control of a T7 promoter including a 63 His-tag introduced
at its amino terminus. Similarly, one-step purification was per-
formed using a Ni-NTA agarose column to obtain homogeneous
protein with expected molecular weight of 46 kDa. Subse-
quently, the CO-bound reduced difference spectra confirmed
the identity of both MycCI and MycG as cytochrome P450
enzymes (see Supplemental Data).
Synthesis of Mycinamicin VIII (M-VIII)
from Protomycinolide IV (PML-IV)
Because of the limited quantity (<0.1 mg) of totally available
M-VIII isolated from M. griseorubida fermentation culture, the952 Chemistry & Biology 15, 950–959, September 22, 2008 ª2008presumed substrate of MycCI, we developed an effective chem-
ical glycosylation strategy to obtain this important intermediate
by coupling desosamine as sugar donor to the readily available
PML-IV aglycone precursor (Hayashi et al., 1981). Glycosylation
with desosamine has previously employed either thioglycosides
or glycosyl fluorides, with a methyl carbonate as the C2 protect-
ing group (Martin et al., 1997; Matsumoto et al., 1988; Suzuki
et al., 1988; Toshima et al., 1995; Woodward et al., 1981a,
1981b, 1981c). After examining several combinations of protect-
ing groups and anomeric leaving groups, we found that the C2
acetoxy-protected glycosyl fluoride of desosamine was conve-
niently obtained, easily purified, stable to storage, and effective
in the transfer of desosamine to a range of aglycones. In this pro-
cedure (Figure 3), erythromycin hydrate was hydrolyzed under
acidic conditions to obtain a crude sample of desosamine hydro-
chloride that was converted to the bis(acetate) of desosamine in
88% isolated yield, as reported elsewhere (Chen et al., 2002).
Further treatment of this material with HF$pyridine afforded the
C2 acetoxy glycosyl fluoride of desosamine 1, which serves as
a stable and convenient precursor for chemical glycosylations.
Direct treatment of PML-IV (Figure 1) with the glycosyl fluoride
and BF3$Et2O in CH2Cl2 afforded C2 acetoxy mycinamycin VIII
as a 2:1 mixture of b and a anomers in 39% (not optimized) iso-
lated yield. Higher yielding desosamine glycosylations with other
mycinamicins have been reported (Matsumoto et al., 1988);
however, these alternative procedures with different glycosyl
donors were not explored for comparison. Purification by pre-
parative HPLC (SiO2) afforded the pure b-anomer (see Supple-
mental Data), which was deprotected with K2CO3 in methanol
to afford semisynthetic M-VIII in 89% isolated yield. The 1H
NMR spectrum of this synthetic material was coincident with
previously reported data (Kinoshita et al., 1989).
Functional Analysis of MycCI In Vitro
To establish the role of each mycinamicin P450, we first tested
whether MycCI is capable of hydroxylating the predicted sub-
strate M-VIII using a typical heterologous spinach ferredoxin
and ferredoxin reductase system (Xue et al., 1998). As expected,Elsevier Ltd All rights reserved
Figure 3. Synthetic Scheme for M-VIII
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product M-VII (Figure 4), albeit inefficiently. Notably, the C- and
N-terminal His-tagged MycCI showed similar activities (data
not shown), indicating that the location of His-tag has no signif-
icant impact on MycCI activity. We selected the C-terminal
His-tagged MycCI to perform biochemical studies and refer to
this form as MycCI for convenience. The low conversion ratio
of M-VIII (11.0 ± 0.8%) might be due to the higher activation
energy required to functionalize the primary C-H bond. Alterna-
tively, the fact that a specific ferredoxin gene mycCII is clustered
with mycCI suggests that MycCI might possess higher ferre-
doxin specificity than MycG. Thus, the capability of MycCII (to-
gether with spinach ferredoxin reductase, since the native ferre-
doxin reductase for MycCI remains unknown) to reconstitute the
in vitro M-VIII hydroxylation activity of MycCI was assessed and
compared to spinach ferredoxin. Thus, when partnered by Myc-
CII-wt and MycCII-NH, MycCI converted 28.6 ± 2.0% and 37.4 ±
1.4% of M-VIII to M-VII, respectively, suggesting MycCII medi-
ates the electron transfer from spinach ferredoxin reductase to
MycCI more efficiently than does spinach ferredoxin (Figure 4).
However, it is currently unclear why the activity of the His-tagged
MycCII is higher than that of MycCII-wt. Considering that spin-
ach ferredoxin and ferredoxin reductase are natural partners,
we reason that the higher activity of MycCII could derive from
a more favorable interaction with the MycCI P450, compared
with the spinach ferredoxin reductase. Therefore, the binding
affinities of different ferredoxins toward MycCI were compared
with one another. As expected, the most active form (MycCII-
NH) exhibited the lowest dissociation constant (Kd) of 7.0 ± 0.1
mM. In contrast, the binding affinity of spinach ferredoxin to
MycCI (Kd = 148.9 ± 10.2 mM) is much lower than that of either
MycCII-wt or MycCII-NH. Interestingly, we found MycCII is un-
able to support in vitro activity of MycG (see Supplemental
Data), the other P450 enzyme involved in mycinamicin biosyn-
thesis. These results strongly suggest MycCII has evolved to
selectively serve MycCI catalysis.
In addition, similar MycCI reactions were assessed with the
PML-IV, M-VI, M-III, M-IV, and M-V (Figure 1), but no products
were observed, and starting materials were quantitatively recov-
ered (data not shown). These results establish that MycCI cata-
lyzes the first oxidation step, converting the C21 methyl group to
the corresponding hydroxymethyl that is subsequently function-Chemistry & Biology 15, 950–alized with 6-deoxyallose, followed by two methylation steps to
mycinose. Moreover, the substrate requires desosamine modifi-
cation at the C5 hydroxyl group in order to be accepted by
MycCI. This is analogous to PikC, shown through cocrystal
structure analysis with natural 12- and 14-membered ring mac-
rolides to involve desosamine-mediated substrate anchoring
(Sherman et al., 2006).
Functional Analysis of MycG In Vitro
Previous genetic studies on the mycinamicin biosynthetic path-
way identified a gene fragment that complemented a M-II non-
producing mutant of M. griseorubida (Inouye et al., 1994). DNA
sequence analysis revealed an open reading frame whose trans-
lated product showed high-level amino acid sequence similarity
to cytochrome P450 enzymes. The mycinamicin biosynthetic in-
termediate isolated from the M-II nonproducing M. griseorubida
strain lacked both C14 hydroxyl and C12-C13 epoxide function-
alities, and the subcloned fragment bearing the putative P450
gene was able to restore production of M-II (Inouye et al.,
1994). These data provided strong but indirect evidence that
the mycG gene product is capable of catalyzing both oxidation
steps at adjacent positions on the macrolactone ring (Figure 1).
To confirm the dual function of MycG, our in vitro analysis was
initiated by testing directly the ability of MycG to convert the pu-
tative substrate M-IV. As shown in Figure 5A, the LC trace of the
reaction extract (2) at 280 nm showed two peaks a and b. The
corresponding mass spectra indicate M-V ([M+H]+ = 712.35)
and M-II ([M+H]+ = 728.35) co-eluted as peak a, and peak
b includes M-IV ([M+H]+ = 696.35) and M-I ([M+H]+ = 712.35).
This LC-MC analysis clearly demonstrates the dual function of
MycG as hydroxylase and epoxidase. However, despite efforts
to optimize reverse-phase HPLC conditions, we were unable
to separate M-IV and M-V from their epoxidized products.
To determine the precursor of M-II, M-V and M-I were incu-
bated with MycG in separate reactions. When M-V was used
as substrate, it was almost completely converted into M-II. Since
M-II (and M-I) lacks strong absorbance at 280 nm (Satoi et al.,
1980), only a minor peak c was observed in the LC trace, al-
though substantial M-II was formed on the basis of mass spec-
tral analysis (Figure 5B; notably, the M-II product was visible at
240 nm). However, M-I was not converted into M-II in vitro (see
Supplemental Data), indicating that M-II can only be generated959, September 22, 2008 ª2008 Elsevier Ltd All rights reserved 953
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Analysis of Mycinamicin Cytochrome P450 EnzymesFigure 4. In Vitro M-VIII Conversions Catalyzed by MycCI
All LC traces were analyzed at 280 nm: (1) negative control, M-VIII + boiled MycCI; (2) M-VIII + MycCI + spinach ferredoxin; (3) M-VIII + MycCI + MycCII-NH; (4) M-
VIII + MycCI + MycCII-wt; and (5) M-VII standard. The right diagram shows M-VIII conversion ratios calculated by using Equation 1-AUCunreacted M-VIII/AUCtotal M-VIII
(AUC: area under curve) based on the corresponding LC-traces in parallel. Error bars are shown since the conversion ratios (mean ± s.d.) are calculated from two
independent experiments. In addition, dissociation constants (Kd) with standard errors of the spinach and MycCII ferredoxins toward MycCI are shown.from M-V as substrate. Epoxidation of M-IV prior to hydroxyl-
ation evidently results in termination of this post-PKS tailoring
pathway (Figure 1).
To assess further enzyme selectivity and ability to catalyze
alternative oxidative reactions against the mycinamicin aglycone
and several early glycosylated intermediates (PML-4, M-VIII, M-
VII, M-VI, and M-III), MycG-mediated reactions were performed.
No products were observed when using PML-4, M-VIII, and M-VII
(see Supplemental Data), but two new compounds appeared at
low levels in LC-MS analysis of the M-VI and M-III reactions
(Figure 5C). When M-III was used as a substrate, a minor new
peak d was detected with m/z = 698.40, which is 16 Da higher
than the molecular weight of M-III. Moreover, in the MycG reac-
tion with M-VI, a new peak e (m/z = 684.25), presumed to be ox-
idized M-VI, was detected at an even lower conversion level. Both
peak d and ewere visible under 280 nm, and their retention times
were faster than corresponding starting materials, strongly sug-
gesting they are hydroxylated instead of epoxidized products.
Moreover, the MS-MS analysis (data not shown) of d and e indi-
cated that both hydroxylations occurred on the macrolactone
ring, although we could not further determine the site of modifica-
tion because of limited amounts of each compound. Interest-
ingly, the C14 hydroxylated forms of M-III and M-VI have already
been reported as minor components of the mycinamicin pathway
designated as mycinamicin IX (M-IX) and mycinamicin XV (M-XV),
respectively (Kinoshita et al., 1992). Accordingly, it is likely that
d and e correspond to M-IX and M-XV, providing direct evidence954 Chemistry & Biology 15, 950–959, September 22, 2008 ª2008for the in vivo origin of these two minor compounds. More impor-
tantly, we established that efficient catalysis by MycG requires
mycinose, derived from dimethylation of the second sugar
residue as C21 OH linked 6-deoxyallose.
Measurement of Substrate Dissociation Constants
To understand why mycinamicin P450 enzymes (especially
MycG) behave differently toward compounds with subtle struc-
tural differences, we performed spectrophotometric substrate
binding assays to determine dissociation constants (Kd). As
shown in Table 1, M-VIII binds to MycCI with a Kd value of 28.1 ±
3.2 mM, which is significantly higher than 0.7 ± 0.1 mM, the
Kd value of M-IV toward MycG. Evidently, the substrate binding
to MycG is much tighter than that to MycCI, which is likely attrib-
uted to additional interactions of mycinose within the P450 sub-
strate-binding pocket. Interestingly, the C14 hydroxylated M-V
showed approximately 14 times lower binding affinity toward
MycG than M-IV, suggesting that M-V is a less suitable substrate
for MycG. However, this finding is inconsistent with the results
from in vitro assays (described in Figure 4C above) in which
M-V was converted to oxidized product more effectively than
M-IV (kinetic analysis [see below] provided insights into this ap-
parent paradox). In contrast to M-V, the epoxidized product M-I
was not able to function as a substrate since we did not observe
a Type-I difference spectra even at high substrate concentra-
tions. This result is consistent with a lack of MycG activity toward
M-I in vitro. It was particularly surprising that the final productElsevier Ltd All rights reserved
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8.4 mM, indicating the compromising effect of the epoxide moiety
toward substrate binding could be overridden by an adjacent
C14 hydroxyl group. The reason for this unusual finding will await
substrate cocrystallographic analysis of MycG, which is
currently in progress.
Steady-State Kinetic Analysis of MycCI and MycG
Assuming a 1:1 stoichiometric relationship between NADPH
consumption and substrate oxidation, the steady-state kinetic
parameters of MycCI were determined using purified synthetic
Figure 5. LC-MS Analysis of In Vitro Con-
versions Catalyzed by MycG
All LC traces were analyzed at 280 nm unless oth-
erwise specified.
(A) MycG reaction using M-IV as substrate: (1)
negative control, M-IV + boiled MycG; (2) M-IV +
MycG. The right panel shows the mass spectra
of peak a and b; (3) M-II standard amplified 203
because of its poor absorbance at 280 nm; (4)
M-V standard; (5) M-I standard amplified 203.
(B) MycG reaction using M-V as substrate: (1) neg-
ative control, M-V + boiled MycG; (2) M-V + MycG.
The inset shows the 240 nm LC trace, under which
M-II has better absorbance. The right panel shows
the mass spectrum of peak c; (3) M-II standard
amplified 203.
(C) MycG reactions using M-III and M-VI as alter-
native substrates: (1) negative control, M-III +
boiled MycG; (2) M-III + MycG; (3) negative con-
trol, M-VI + boiled MycG; (4) M-VI + MycG. LC
traces (3) and (4) amplified 20 3 compared to (1)
and (2) to visualize the peak e in trace amount.
The right panel shows the mass spectra of peak
d and e.
M-VIII as substrate. When partnered with
spinach ferredoxin, MycCI demonstrated
a Km of 34.5 ± 5.5 mM and a kcat of 71.7 ±
3.2 min1 for the C21 methyl group hy-
droxylation step. In contrast, with Myc-
CII-NH coupled with MycCI, catalysis
became more efficient with a decreased
Km of 5.8 ± 0.7 mM and an improved kcat
of 104.1 ± 1.8 min1. This finding suggests
that MycCII not only induces better sub-
strate binding of MycCI but also improves
electron transfer efficiency as reflected
by increased turnover number (kcat).
Although MycG is capable of catalyz-
ing three different reactions (M-IV to
M-V; M-IV to M-I; and M-V to M-II), we
limited our study to kinetic constants for
M-V to M-II conversion (Km = 16.2 ±
3.1 mM; kcat = 415.7 ± 22.9 min
1). This
was because of the complexity of the
analysis when M-IV was used as sub-
strate, since multiple reactions (M-IV to
M-V or M-I and M-V to M-II) did not allow
fitting of data to the Michaelis-Menten
equation. However, it is noteworthy that we observed the overall
NADPH consumption rate at high M-IV concentration (e.g.,
100 mM) to be considerably reduced, compared with low M-IV
concentration (e.g., 10 mM), suggesting strong substrate inhibi-
tion. This could explain the above-mentioned contradiction
between the conversion ratio and binding affinity. According to
the in vitro analysis of MycG activity (Figures 5A and 5B), M-V
appears to be a better substrate than M-IV on the basis of the
conversion ratios. However, this result might be misleading since
M-IV has better binding affinity toward MycG (Table 1). Thus, on
the basis of in vitro reactions using substrate concentrations at
Chemistry & Biology 15, 950–959, September 22, 2008 ª2008 Elsevier Ltd All rights reserved 955
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Enzyme Substrate Kd (mM) Km (mM) kcat (min
1) kcat/Km (mM
1$ min1)
MycCI M-VIII 28.1 ± 3.2 34.4 ± 5.5a 71.7 ± 3.2a 2.1a
5.8 ± 0.7b 104.1 ± 1.8b 17.9b
MycG M-IV 0.7 ± 0.1 NDc NDc NDc
M-V 10.4 ± 0.2 16.2 ± 3.1a 415.7 ± 22.9a 25.7a
M-I NBd   
M-II 71.5 ± 8.4   
, No reaction.
a Kinetic parameters were determined when spinach ferredoxin was used.
b Kinetic constants were determined when MycCII-NH ferredoxin was used.
c ND: The kinetic parameters were not determined because multiple reactions occur at the same time.
d NB: No binding.500 mM, we believe that the lower conversion of M-IV is a reflec-
tion of substrate inhibition.
DISCUSSION
Mycinamicins represent a large family of macrolide antibiotics
with more than 20 members (Kinoshita et al., 1991b, 1992).
The structural diversity is derived primarily from post-PKS tailor-
ing modifications, including glycosylation, oxidation, and meth-
ylation steps. Therefore, this biosynthetic pathway represents
an important system to explore the mechanism and significance
of secondary metabolite diversification.
Here, we provide a detailed analysis of two cytochrome P450
enzymes, MycCI and MycG, and their role in late-stage chemical
modifications. By gene cloning, protein expression, purification,
and reconstitution assays with heterologous redox partners, we
unambiguously confirmed their physiological role in vitro. To the
best of our knowledge, the functional and kinetic analysis of
MycCI represents the first enzymatic characterization of a bio-
synthetic monooxygenase responsible for methyl group hydrox-
ylation. In addition, we established that MycCII is a specific
ferredoxin, whose corresponding gene (mycCII) is immediately
adjacent to mycCI and capable of effectively supporting MycCI
activity. Compared with spinach ferredoxin, MycCII binds to
MycCI more tightly, presumably leading to more efficient elec-
tron transfer. On the other hand, we established that C21 hydrox-
ylation by MycCI depends on C5-linked desosamine, which is
analogous to PikC (Xue et al., 1998), another cytochrome P450
involved in pikromycin biosynthesis. Recent cocrystallographic
analysis of PikC (Sherman et al., 2006) and its natural substrates
(YC-17 and narbomycin) revealed that desosamine acts as an
indispensable anchor responsible for productive binding and
proper positioning of substrate in the active site. Accordingly,
we surmise that desosamine plays a similar role in hydroxylation
of precursor macrolide M-VIII.
The current study has revealed that MycG is a more versatile
enzyme than MycCI, providing the first example of a biosynthetic
P450 involved physiologically in catalyzing both hydroxylation
and epoxidation reactions. In addition, MycG represents the
primary basis for structural diversification in the mycinamicin
pathway since it is solely responsible for generating multiple
products, including M-V, M-I, and M-II, as well as some minor
components, including M-IX and M-XV. This work has also dem-956 Chemistry & Biology 15, 950–959, September 22, 2008 ª2008onstrated that MycG function depends on the presence of both
desosamine and the second sugar mycinose in the substrate. It
is also noteworthy that both deoxysugars are essential for myci-
namicin bioactivity (Kinoshita et al., 1989). Although the precise
role of the second sugar for MycG substrate recognition remains
obscure because of the lack of X-ray structural information, on
the basis of the high binding affinity of M-IV toward MycG
(Kd = 0.7 ± 0.1 mM), we predict that there might be a specific
active site-binding pocket in the polypeptide to accommodate
mycinose, thereby significantly improving substrate affinity.
Moreover, of particular interest, the activity of MycG against
diglycosylated substrates (M-VI, M-III, and M-IV) is related to
the extent of methylation mediated by sequential O-methyltrans-
fer by MycE and MycF. In the absence of methylether groups
installed on the second sugar molecule, M-VI bearing 6-deoxyal-
lose appears to be a very poor substrate for MycG. This situation
can be improved by the first methylation to form javose in M-III,
although its conversion is low (Figure 5C). Subsequently, the
second methylation catalyzed by MycF imparts a pronounced
effect upon MycG-mediated binding of M-IV. It appears likely
that these stepwise methylations decrease the polarity of 6-de-
oxyallose in M-VI, thus enabling it to be accepted by a putative
hydrophobic MycG-binding pocket.
Substrate inhibition occurs in about 20% of all known en-
zymes (Copeland, 2000). In biosynthetic P450 enzymes, this
phenomenon has been observed in previous kinetic analysis
of PikC (Li et al., 2007), EryK (Lambalot and Cane, 1995),
and PimD (Mendes et al., 2005). In this study, M-IV inhibition
of MycG was also detected indirectly even though the kinetic
parameters were not obtained because of the complexity of
the multiple-reaction system. Thus, the mechanism of this
substrate inhibition cannot be further elucidated without gener-
ating detailed kinetic curves. However, we realize that this
behavior of MycG might be physiologically significant for main-
taining the chemical diversity within the mycinamicin pathway.
In the event that M-IV inhibition does not occur, MycG would
convert all M-IV into final products M-I and M-II, instead of
a mixture of M-I, II, IV, and V as shown in Figure 5A and ob-
served in the fermentation culture of M. griseorubida strain
A11725 (Satoi et al., 1980). This would ultimately limit the spec-
trum of its metabolic output and perhaps compromise the abil-
ity of the microorganism to adapt to a variable and competitive
environment.Elsevier Ltd All rights reserved
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This report provides detailed information about the oxidative
cascade that introduces structural diversity into themycina-
micin class of macrolide antibiotics. We have established
in vitro thatMycCI is a cytochromeP450 enzyme responsible
for the C21 methyl hydroxylation of M-VIII, the starting sub-
strate of the mycinamicin post-PKS tailoring pathway. In
addition, we have demonstrated that the MycG mono oxy-
genase catalyzes sequential hydroxylation and epoxidation
steps with M-IV or M-V as substrates. MycCI represents the
first biosynthetic methyl group hydroxylase characterized
in vitro. Its optimal activity depends on MycCII, a ferredoxin
whose gene is encodedwithin themycinamycin biosynthetic
gene cluster. MycG is the first biosynthetic mono oxygenase
to be characterized whose physiological function includes
hydroxylation and epoxidation reactions. Moreover, the un-
precedented requirement of the second deoxysugarwith es-
sentialmethylethermodifications foractivityofMycGreveals
the important interplay between three typical posttailoring
modifications in biosynthesis, includingglycosylation,meth-
ylation, and oxidation. Through detailed functional analysis
of these two P450 enzymes, we have unambiguously estab-
lished the mycinamicin post-PKS oxidation pathway.
EXPERIMENTAL PROCEDURES
Materials
Unless otherwise specified, all chemical reagents were ordered from Sigma-
Aldrich. DNA oligonucleotides were purchased from Integrated DNA Technol-
ogies (Coralville, IA). Molecular cloning used New England Biolabs (Ipswich,
MA) restriction enzymes, Stratagene (La Jolla, CA) Pfu Turbo DNA polymerase,
Novagen (Madison, WI) pET vectors, Invitrogen (Carlsbad, CA) T4 DNA ligase,
and Z-Competent Escherichia coli Transformation Buffer set from Zymo
Research (Orange, CA). Protein purification used QIAGEN (Valencia, CA) Ni-
NTA resin, Millipore (Billerica, MA) Amicon Ultra centrifugal filter, PD-10 desalt-
ing columns from GE Healthcare (Piscataway, NJ), and Thrombin restriction
grade Kit from Novagen (Madison, WI). LB Broth was from EM Sciences
(Gibbstown, NJ). All mycinamicins except M-VIII were obtained from the
fermentation broth of M. griseorubida A11725. M-VIII was synthesized from
PML-IV using the method described above.
DNA Manipulation, Cloning, and PCR
Using cosmid pMR01 (Anzai et al., 2003) as template, mycCI, mycCII, and
mycG genes were amplified by PCR under standard conditions with primers
as follows: forward, 50-CAGCATATGGTGGTCTGGCCCATGGACCGCACCT
G-30 for mycCI, 50-GTGCCATATGCGGATAGTCCTGGACGCCGAAC-30 for
mycCII, and 50-CGGTCATATGACTTCAGCTGAACCTAGGGCGTATCC-30 for
mycG (the underlined bases represent the introducedNdeI site for further clon-
ing); reverse, 50-TCGTAAGCTTCCACTCGACCAGCAGCTCGTCGATG-30 for
cloning mycCI gene without a stop codon, 50-TCCAAAGCTTTCCGCATACCG
CACCCCCATTCGTC-30 for amplifying the mycCI gene retaining a stop codon,
50-TGACAAGCTTACTCCTGTTGGCCCACCTGTCCCGTG-30 for mycCII, and
50-GGCAAAGCTTCTCCGACGAGATCGTCGAGATCGAC-30 for mycG (the
italic letters indicate a HindIII restriction site for later cloning). The gel purified
cDNAs were rescued by double digestion of NdeI and HindIII. Then, the frag-
ment containing the mycCI gene with stop codon removed was ligated into
NdeI/HindIII treated pET21b to generate recombinant plasmid pET21b-mycCI
for expression of C-terminal His-tagged MycCI. Genes retaining stop codons,
including mycCI, mycCII, and mycG, were ligated into previously NdeI/HindIII-
digested pET28b to generate recombinant plasmids for expression of N-termi-
nal His-tagged proteins. After confirming the identity of inserted genes by DNA
sequencing, the constructs were used to transform E. coli BL21(DE3) for
protein overexpression.Chemistry & Biology 15, 950–Protein Overexpression and Purification
MycCI and MycG (P450s) overexpression and purification followed previously
developed procedures with minor modifications (Li et al., 2007; Xue et al.,
1998). The E. coli BL21 (DE3) transformants carrying certain plasmids were
grown at 37C in 1 l of LB broth containing thiamine (1 mM), 5% glycerol,
50 mg/ml selective antibiotics (ampicillin for pET21b and kanamycin for
pET28b), and a rare salt solution (6750 mg/l FeCl3, 500 mg/l ZnCl2, CoCl2,
Na2MoO4, 250 mg/l CaCl2, 465 mg/l CuSO4, and 125 mg/l H3BO3) until OD600
reached 0.6–0.8. Then isopropyl b-D-thiogalactoside (IPTG, 0.1mM) and
d-aminolevulinic acid (1mM) were added, and the cells were cultured at
18C overnight. After harvesting cells by centrifugation, 40 ml of lysis buffer
(50 mM NaH2PO4 [pH 8.0], 300 mM NaCl, 10% glycerol, and 10 mM imidazole)
was used to resuspend the cell pellet. Lysis was accomplished on a Model 500
Sonic Dismembrator (ThermoFisher Scientific). The insoluble material was
separated by centrifugation (35,000 3 g, 30 min at 4C). The soluble fraction
was collected and incubated for 1 h at 4C after addition of 1ml Ni-NTA resin.
The slurry was loaded onto an empty column, and the column was then
washed with 40 to 80 ml of wash buffer (50 mM NaH2PO4 [pH8.0], 300 mM
NaCl, 10% glycerol, and 20–30 mM imidazole). The elution buffer (50 mM
NaH2PO4 [pH8.0], 300 mM NaCl, 10% glycerol, and 250 mM imidazole) was
added onto the column, and eluted protein fraction was concentrated with
Amicon Ultra 4, Ultracel 30K. Subsequent desalting was attained by buffer
exchange into desalting buffer (50 mM NaH2PO4 [pH7.3], 1 mM EDTA,
0.2 mM dithioerythritol, and 10% glycerol) with a PD-10 column.
Overexpression and purification of N-terminal 63 His-tagged ferredoxin
MycCII-NH are similar to above procedures with minor modifications as
follows: 1) d-aminolevulinic acid, the precursor for heme biosynthesis, was
omitted in the culture broth; and 2) the protein obtained from elution buffer
was concentrated using Amicon Ultra 4, Ultracel 5K because of the low
molecular weight of MycCII (10 kDa). To obtain MycCII-wt lacking a His-
tag, 2.4 mg of MycCII-NH in desalting buffer was digested by 2 units of throm-
bin at 4C overnight. The cleaved His-tag and residual thrombin were removed
by use of Ni-NTA resin and a 30K size exclusion filter sequentially. The concen-
tration of purified ferredoxins was determined by Coomassie protein assay
using spinach ferredoxin as standard.
CO-Bound Reduced Difference Spectra
The identification of MycCI and MycG as active P450 enzymes was performed
through getting the CO-bound reduced difference spectra using a UV-visible
spectrophotometer 300 Bio (Cary). First, the P450 enzyme in desalting buffer
was reduced by adding several milligrams of sodium dithionite (Na2S2O4), and
a spectrum was recorded from 350 to 600 nm. Then, after CO bubbling of the
solution for 30–60 sec, the spectrum of CO-bound reduced P450 species was
recorded using previous reduced spectrum as reference. This assay was also
used to determine the functional P450 concentration using the extinction
coefficient of 91,000 M1$cm1 (Omura and Sato, 1964).
Functional Analysis of In Vitro Activities of MycCI and MycG
The standard conversion was accomplished by combining 1 mM of desalted
MycCI or MycG, whose functional concentrations were determined using
UV-visible absorption spectrum method (Omura and Sato, 1964), 0.5 mM my-
cinamicin biosynthetic intermediate, 3.5 mM spinach ferredoxin or MycCII fer-
redoxin, 0.1 U/ml spinach ferredoxin-NADP+ reductase, and 0.5 mM NADPH in
100 ml of desalting buffer. The reaction with boiled P450 enzyme was used as
a negative control. The reaction was performed for 2 h at 30C and was termi-
nated by extraction, using 33 200 ml of CHCl3. The resulting organic extraction
was dried and redissolved in 150 ml of methanol. The LC-MS analysis of reac-
tion extract was performed on LCMS-2010 EV (Shimadzu) by using an
XBridge C18 3.5 mm 150 mm reverse-phase HPLC column under following
conditions: mobile phase, 20–100% solvent B over 18 min (A = deionized
water + 0.1% formic acid, B = acetonitrile + 0.1% formic acid); flow rate:
0.2 ml/min; UV wavelength: 240 and 280 nm.
Spectral Substrate Binding Assay
Spectral substrate binding assay was performed on UV-visible spectropho-
tometer 300 Bio (Cary) at room temperature by titrating substrate DMSO solu-
tion (blank DMSO for reference group) into 1 ml of 0.5–1 mM P450 solution in
1 ml aliquots. The series of Type I difference spectra were used to deduce959, September 22, 2008 ª2008 Elsevier Ltd All rights reserved 957
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Analysis of Mycinamicin Cytochrome P450 EnzymesDA (Apeak  Atrough). Then, the data from duplicated experiments were fit to Mi-
chaelis-Menten equation to obtain the dissociation constant Kd.
Spectral Ferredoxin Binding Assay
Spectral ferredoxin titrations were performed as described elsewhere (Cogh-
lan and Vickery, 1991) using 0.7 mM MycCI and 10 mM M-VIII in desalting buffer
at room temperature. Ferredoxin solutions in appropriate concentrations were
used to titrate the P450 solution. Binding of ferredoxins to MycCI induced
increased M-VIII binding, thus leading to a larger absorbance difference DA
(Apeak  Atrough). The data from duplicated experiments were linearized by
using a Hanes-Wolf plot to deduce dissociation constant Kd.
Steady-State Kinetics of MycCI and MycG
The standard reactions contain 0.6 mM of MycCI (when partnered with spinach
ferredoxin), 0.1 mM of MycCI (when partnered with MycCII-NH), or 0.1 mM of
MycG, 1.9 mM spinach or MycCII ferredoxins, 0.02 U/ml spinach ferredoxin-
NADP+ reductase, 5–200 mM M-VIII for MycCI and 2–160 mM M-V for MycG
in 90 ml of desalting buffer. After preincubation in 96-well plate at room temper-
ature for 5 min, the reactions with different substrate concentrations were
initiated spontaneously by adding 10 ml of 2 mM NADPH with a multichannel
pipette. The rate of NADPH consumption was monitored continuously over
2 min under 340 nm by SpectraMax M5 spectrophotometer (Molecular
Devices). The initial velocities of NADPH consumption were deduced from
the absorbance curves within the linear range (0–20 s). Then, assuming a 1:1
stoichiometric relationship between NADPH consumption and substrate
oxidation, the initial velocities of hydroxylation reactions were calculated by us-
ing the millimolar absorption coefficient 6.22 mM1$cm1 of NADPH at 340 nm
(Greenbaum et al., 1972). Finally, the results from duplicated experiments were
fit to Michaelis-Menten equation to obtain steady-state kinetic parameters.
SUPPLEMENTAL DATA
Supplemental data include five figures and can be found with this article online
at http://www.chembiol.com/cgi/content/full/15/9/950/DC1/.
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